We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
Previous Close | 2.1500 |
Open | 2.1200 |
Bid | 2.1800 x 0 |
Ask | 2.1900 x 0 |
Day's Range | 2.1000 - 2.2000 |
52 Week Range | 1.2200 - 6.4800 |
Volume | |
Avg. Volume | 83,473 |
Market Cap | 106.768M |
Beta (5Y Monthly) | 1.61 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.6700 |
Earnings Date | Feb 26, 2024 - Mar 01, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.43 |
Today announced receipt of the 2023 Industrial Research Sectoral Group (RSRI) Innovation Award from ...
Honor awarded last night recognizes Theratechnologies and Prof. Borhane Annabi for advancing preclinical development of sudocetaxel zendusortide for treatment of triple-negative breast cancerMONTREAL, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research Sectoral Group (RSR
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement datedDecember 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. Common shares priced at US$1.00 per share MONTREAL, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that i
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the launch of a marketed public offering (the “P
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced further changes to its operations that will see
Data presented at AMCP Nexus 2023 highlight implications for U.S. payers based on cost-effectiveness and improved outcomes This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the
- Revised the Minimum Liquidity Covenant for All Times Following October 31, 2023 to be Between US$15 Million and US$20 Million - Minimum Quarterly Revenue Covenant Replaced with Minimum Adjusted EBITDA Covenant - Deleted Prohibition Against Having a Going Concern Note in the Opinion of the Company’s Auditors that Accompanies the Company’s Annual Report This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its
Significant reduction in INSTI-associated VAT accumulation with tesamorelin contrasts with VAT increase in patients taking placebo VAT accumulation observed after 12 months on INSTI-containing regimens, even in the absence of significant weight or body mass index changesResults also show a reduction in hepatic fat fraction in people taking tesamorelin This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its s
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced results from a study evaluating an intramuscula
Symbol | Last Price | Change | % Change |
---|---|---|---|
ONC.TO Oncolytics Biotech Inc. | |||
GUD.TO Knight Therapeutics Inc. | |||
RVX.TO Resverlogix Corp. | |||
HRX.TO Héroux-Devtek Inc. | |||
MBX.TO Microbix Biosystems Inc. |
Symbol | Last Price | Change | % Change |
---|---|---|---|
APS.TO Aptose Biosciences Inc. | |||
ONC.TO Oncolytics Biotech Inc. | |||
APTO Aptose Biosciences Inc. | |||
AEZS.TO Aeterna Zentaris Inc. | |||
MBX.TO Microbix Biosystems Inc. |
Maintains | JonesTrading: Buy to Buy | 2023-07-17 | |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 2023-07-13 | |
Initiated | Cantor Fitzgerald: to Overweight | 2022-11-17 | |
Downgrade | Canaccord Genuity: Buy to Hold | 2021-07-29 | |
Maintains | Canaccord Genuity: to Buy | 2021-04-19 | |
Maintains | Canaccord Genuity: to Buy | 2020-04-15 |
2015 Peel Street
11th Floor
Montreal, QC H3A 1T8
Canada
514 336 7800
https://www.theratech.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 144
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; and TH1902, which is in Phase 1 clinical trials for the treatment of various solid tumors, including HR+ breast cancer, triple negative breast cancer, ovarian cancer, endometrial cancer, melanoma, thyroid cancer, small cell lung cancer, and prostate cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.